NCT01481051

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Mati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.

Conditions

• Glaucoma
• Ocular Hypertension (OH)

Interventions

Type	Name	Description
DRUG	Latanoprost-PPDS	Sustained delivery for 12 weeks

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-11-29
• Last updated: 2013-09-26

Locations

6 sites across 1 country: United States